New York, NYNCT07049055Now EnrollingIRB Ready

Pancreatic Cancer, Metastatic Clinical Trial in New York, NY

Access cutting-edge pancreatic cancer, metastatic treatment through this phase 1/2 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Engeneic Pty Limited

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access pancreatic cancer, metastatic specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic cancer, metastatic treatment provided free

Apply for This New York Location

Check if you qualify for this pancreatic cancer, metastatic clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Pancreatic Cancer, Metastatic Study in New York

The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.

Sponsor: Engeneic Pty Limited

Who Can Participate

Inclusion Criteria

Histological or pathological confirmation of metastatic pancreas adenocarcinoma. Cytological or histological evidence of metastatic disease is required.
Male or Female greater than or equal to 18 years of age.
Eastern Cooperative Oncology Group (ECOG) performance score of 0-1.
Life expectancy ≥ 3 months in the opinion of the Investigator.
Measurable disease as per iRECIST criteria.
Subjects must have tumors that express EGFR.
Documented disease progression with first line FOLFIRINOX or NALIRIFOX therapy, during or within 3 months (+/- 15 days) after end of therapy.
No more than one line of prior systemic therapy for metastatic PDAC allowed.
Albumin level \> 3.0 g/dl
Adequate hematological function.
Adequate renal function.
Adequate hepatic function.
Adequate cardiac function with LVEF ≥ 50% at baseline.
Reproductive criteria as follows:
Female subjects who are of non-reproductive potential
Female subjects of childbearing potential must have a negative serum pregnancy test within 14 days of the first dose.
Female subjects must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study drug administration.
Male subjects must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study drug administration.
All study subjects must be willing to ensure that corresponding sexual partners practice these same methods of highly effective birth control for the same duration.
The subject (or subject's legally authorized representative) has provided voluntary signed informed consent.
According to the investigator's assessment, subject will be able to comply with the study protocol.

Exclusion Criteria

Subjects currently receiving any other investigational agent.
Unresolved (≥ Grade 1) non-hematological adverse events from prior anti-cancer therapy that is not controlled on maximal supportive therapy.
Significant pericardial effusions, pleural effusions, or ascites that requires intervention. Subjects who require drainage within the last four weeks are ineligible.
History of leptomeningeal or brain/CNS metastases.
Ongoing treatment for other malignancies (hormone therapy acceptable).
Patient may not have a history of malignancy other than PDAC within two years prior to screening except in circumstances where the risk of recurrence, metastasis or death in 5-years is \<10%.
Concurrent unstable diabetes mellitus or other contraindications for the use of corticosteroids that requires active titration of insulin.
Subject has experienced a history of uncontrolled coronary artery disease, with or without angina pectoris or myocardial infarction, symptomatic congestive heart failure (New York Heart Association \> Class II)
Uncontrolled hypertension (systolic \> 180 mmHg or diastolic \> 100 mmHg) within two weeks.
Uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy within the last four weeks.
Baseline QTcF ≥ 450 ms (males) or ≥ 470 ms (females).
Uncontrolled HIV infection. Patients without a prior diagnosis of HIV infection will undergo HIV testing unless not permitted to do so under local regulations. Patients with known HIV who have controlled infection (viral load undetectable and a CD4 count \>350 either spontaneously or on a stable antiviral regimen) are permitted.
Uncontrolled Hepatitis B virus (HBV) infection (chronic or acute).
Uncontrolled Hepatitis C virus (HCV) infection.
Uncontrolled arterial or venous thrombosis.
Active or uncontrolled severe infection.
Uncontrolled hypercalcemia (\>2.6mmol/L or \>10.3mg/dL) or symptomatic hypercalcemia requiring continued treatment for hypercalcemia.
Received the following procedures within 21 days to receiving their first dose (or has not recovered from the toxic effects of such therapy) including:
other investigational therapy
radiotherapy
any major surgery.
Prior other therapies or procedures prior to receiving their first dose:
QTc interval prolonging medicines should be reviewed and where possible their use should be minimized and alternate medicines that are not QTc interval prolonging, considered as substitutes.
Known allergy/hypersensitivity to investigational components or excipients (trehalose, monoclonal antibody infusions, interferon therapy, or ciprofloxacin HCl (or other quinolones).
Female who is pregnant or breastfeeding.
Subject who cannot comply with protocol scheduled study visits or procedures, to the best of the subject and Investigator's knowledge.
Any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.
History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the Investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07049055) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Cancer, Metastatic Treatment Options in New York, NY

If you're searching for pancreatic cancer, metastatic treatment options in New York, NY, this clinical trial (NCT07049055) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced pancreatic cancer, metastatic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic cancer, metastatic clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in New York, NY

See all pancreatic cancer clinical trials recruiting in New York — not just this study.

Browse Pancreatic Cancer Trials in New York →

Browse More Trials by Condition

Pancreatic Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY